title: Long-term efficacy of vildagliptin in patients with type 2 diabetes undergoing hemodialysis.
abstract: BACKGROUND
  There are few studies evaluating long-term glycemic control using a dipeptidyl peptidase-4 inhibitor in type 2 diabetes patients with end-stage renal disease (ESRD). The aim of this study was to evaluate the safety and efficacy of vildagliptin therapy over 2 years in type 2 diabetes with ESRD.
  
  
  METHODS
  Patients with ESRD resulting from type 2 diabetes requiring dialysis who had ≥20 % glycated albumin (GA) were enrolled. Vildagliptin 50 mg once daily was administered for 2 years. Changes in GA and dry weight were evaluated.
  
  
  RESULTS
  In 32 patients (24 men and 8 women) aged 68.3 ± 1.9 years, vildagliptin 50 mg once daily was administered for 2 years, but the dose was increased to 50 mg twice daily in 15 patients. GA was significantly reduced by 2.6 ± 0.6 %, from 22.4 ± 0.6 % at baseline to 19.8 ± 0.4 % at 2 years. After 2 years of vildagliptin therapy, 15 (46.9 %) of 32 patients achieved a GA level of <20 %. Dry weight changed slightly, with an increase of 1.3 ± 0.8 kg at 2 years. No adverse drug reactions related to treatment with vildagliptin were seen.
  
  
  CONCLUSIONS
  Vildagliptin is a promising therapeutic option for safe, effective glycemic control in type 2 diabetic patients with ESRD.
authors.affiliation: Department of Hemodialysis, Shinsen Ikebukuro Clinic, Tobu Annex Bldg. 4F, 1-10-10, Nishi-Ikebukuro, Toshima-ku, Tokyo, 171-0021 Japan.
authors.forename: Jun-Ichiro
authors.initials: J
authors.lastname: Mera
authors.affiliation: Department of Urology, Higashi-Omiya General Hospital, 5-18, Higashi-Omiya, Minuma-ku, Saitama, 337-0051 Japan.
authors.forename: Eiko
authors.initials: E
authors.lastname: Okada
authors.affiliation: Department of Nephrology, Bousei Hospital, 1-8-14, Harigaya, Urawa-ku, Saitama, 330-0075 Japan.
authors.forename: Masumi
authors.initials: M
authors.lastname: Okuda
authors.affiliation: Department of Nephrology, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo, 173-8606 Japan.
authors.forename: Tatsuru
authors.initials: T
authors.lastname: Ota
authors.affiliation: Department of Nephrology, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo, 173-8606 Japan.
authors.forename: Shigeru
authors.initials: S
authors.lastname: Sibata
authors.affiliation: Department of Nephrology, Teikyo University School of Medicine, 2-11-1, Kaga, Itabashi-ku, Tokyo, 173-8606 Japan.
authors.forename: Shunya
authors.initials: S
authors.lastname: Uchida
keywords: Glycated albumin; Hemodialysis; Type 2 diabetes; Vildagliptin